^
Association details:
Biomarker:NTRK3 fusion
Cancer:Solid Tumor
Drug:zurletrectinib (ICP-723) (pan-TRK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.

Published date:
05/26/2022
Excerpt:
According to RECIST 1.1 criteria, among the 6 patients with NTRK fusion, the overall response rate (ORR) was 66.7% (4 patients with partial response (PR)), the disease control rate (DCR) was 100%. It is worth noting that one patient with measurable brain metastasis achieved PR with the target brain lesion shrunk from 10 mm to 3 mm. All patients who achieved PR responded to ICP-723 at the first tumor assessment after 4-week treatment and maintained sustained responses to the date of data cutoff. ICP-723 is safe and well-tolerated in patients with advanced solid tumors. Encouraging clinical efficacy including intracranial activity was demonstrated in patients with NTRK gene fusion in various tumor types.
DOI:
10.1200/JCO.2022.40.16_suppl.3106
Trial ID: